Supernormal Oxygen Delivery for Patients With Severe Burns

Burn Surgery Clinical Trial

Official title:

Supernormal Oxygen Delivery for Patients With Severe Burns：A Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05241912
• Other study ID #: 2022-005-01
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: February 28, 2022
• Est. completion date: June 1, 2023

Study information

• Verified date: January 2022
• Source: Guangzhou Red Cross Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized double-blinded study to investigate in which the groups are designated as the control group and the goal-directed fluid therapy group to further evaluate significant differences in rate of complications during burn surgery.

Description:

This is a randomized double-blinded study to investigate the effect of control group and the goal-directed fluid therapy group on complications during surgery of the burn patients. The groups are designated as the control group and the oal-directed fluid therapy group to further evaluate significant differences in complications during the surgery.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Severe burn patients

Exclusion Criteria:

• Patients or families refuse to sign consent

Related Conditions & MeSH terms

• Burn Surgery
• Burns

Intervention

Drug:
• Dobutamine
administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery

Locations

Country	Name	City	State
China	Guangzhou Red cross hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Red Cross Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complication	perioperative complications	One week after operation